biOasis Announces the Issuance of an Additional US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

VANCOUVER, BC--(Marketwired - July 10, 2016) - biOasis Technologies Inc. (BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent covering a refined subset of fragments found within Melanotransferrin or P97 for the delivery of therapeutic agents to the brain.

The U.S. Patent, No. 9,364,567, was issued on June 14, 2016 and is entitled, "Fragments of P97 and Uses Thereof." The patent significantly broadens the biOasis Transcend Platform that was originally based on the protein known as melanotransferrin (MTf or p97). This issuance caps the long journey to firm up the company's intellectual property and it greatly strengthens the company's licensing model.

Commented CEO Rob Hutchison, "The biOasis business model is based on the strength of our core assets, the intellectual property that is protected by our broad patent portfolio. Over the past seven years we have been focused on one goal, conducting extensive research programs to secure patents that enable us to commercialize our Transcend technology. As part of a layered approach with our protection strategy, this patent not only broadens the prior fragment patent protection, but also deals with very broad uses for the Transcend Platform, in the fields of Oncology, Lysosomal Storage Diseases, Gene Therapy, to name a few and represents a highly significant component of our licensing business model."

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Richmond, B.C., Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.